Study results unveiled at ASCO show combining Enhertu with Perjeta can significantly delay tumor growth versus a regimen that ...

The PD-(L)1xVEGF field had a roller coaster week marked by an imperfect readout and a potentially $11 billion deal. | The PD- ...

Each year, the American Society of Clinical Oncology annual meeting brings together the biggest names and brightest minds in ...

The DESTINY-Breast09 study, reported at ASCO, compared antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) and ...

Enhertu, Datroway and other antibody-drug conjugates developed by Daiichi Sankyo have made the company a leader in a ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...

The cancer drug Enhertu stalled the growth of tumors by well over a year in a group of women with a type of metastatic but ...

New hope is on the horizon in the fight against cancer. At this year’s American Society of Clinical Oncology (ASCO) annual ...

A slow ascent for more than two decades has given way to a sharp rise in important ADC readouts, marking a milestone era for targeted treatments.

Adding Enhertu to Perjeta improved time without cancer growth versus standard care in advanced HER2-positive breast cancer, ...

Daiichi Sankyo and AstraZeneca’s ENHERTU demonstrated a median overall survival of 14.7 months Results reinforce second-line use of ENHERTU globally in this setting ENHERTU is a specifically ...

Daiichi Sankyo and AstraZeneca’s ENHERTU plus pertuzumab showed a median progression-free survival greater than three years First trial in more than a decade to demonstrate an improvement in ...